BioGaia - Public Comps and Valuation Multiples

BioGaia Overview

About BioGaia

BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

Founded

1990

HQ

Employees

164

Website

biogaia.se

Sectors

Nutraceuticals & Cosmeceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $145M

LTM EBITDA $50.3M

EV

$890M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

BioGaia Financials

BioGaia has a last 12-month revenue of $145M and a last 12-month EBITDA of $50.3M.

In the most recent fiscal year, BioGaia achieved revenue of $141M and an EBITDA of $53.6M.

BioGaia expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BioGaia valuation multiples based on analyst estimates

BioGaia P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$129M	$141M	XXX	XXX	XXX
Gross Profit	$79.6M	$94.4M	XXX	XXX	XXX
Gross Margin	62%	67%	XXX	XXX	XXX
EBITDA	$49.1M	$53.6M	XXX	XXX	XXX
EBITDA Margin	38%	38%	XXX	XXX	XXX
Net Profit	$37.1M	$36.3M	XXX	XXX	XXX
Net Margin	29%	26%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

BioGaia Stock Performance

As of April 21, 2025, BioGaia's stock price is SEK 101 (or $10).

BioGaia has current market cap of SEK 10.2B (or $1.0B), and EV of SEK 9.0B (or $890M).

See BioGaia trading valuation data

BioGaia Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$890M	$1.0B	XXX	XXX	XXX	XXX	$0.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

BioGaia Valuation Multiples

As of April 21, 2025, BioGaia has market cap of $1.0B and EV of $890M.

BioGaia's trades at 6.1x LTM EV/Revenue multiple, and 17.7x LTM EBITDA.

Analysts estimate BioGaia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for BioGaia and 10K+ public comps

BioGaia Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$890M	XXX	XXX	XXX
EV/Revenue	6.3x	XXX	XXX	XXX
EV/EBITDA	16.6x	XXX	XXX	XXX
P/E	29.0x	XXX	XXX	XXX
P/E/Growth	2.1x	XXX	XXX	XXX
EV/FCF	25.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioGaia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

BioGaia Valuation Multiples

BioGaia's NTM/LTM revenue growth is 10%

BioGaia's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $0.4M for the same period.

Over next 12 months, BioGaia's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate BioGaia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for BioGaia and other 10K+ public comps

BioGaia Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	10%	XXX	XXX	XXX	XXX
EBITDA Margin	38%	XXX	XXX	XXX	XXX
EBITDA Growth	9%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	48%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.9M	XXX	XXX	XXX	XXX
Opex per Employee	$0.4M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	30%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	3%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	11%	XXX	XXX	XXX	XXX
Opex to Revenue	43%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Streaming Platforms

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Explore Valuation Multiples by Industry